News and Trends 5 Jul 2022 Mogrify and Astellas to address sensorineural hearing loss Biopharma company Mogrify Limited, and Japanese regenerative medicine firm Astellas Pharma Inc., have announced a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss. Utilizing Mogrify’s direct cellular reprogramming platform, the collaboration will seek to identify novel combinations of transcription factors involved in cell differentiation to generate new cochlear hair […] July 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Positive news from trial for drug to treat major depressive disorder A company working on treatments for people with mental health issues has had positive feedback from the development program of an anti-depressant targeting major depressive disorder (MDD). ANeuroTech has just announced that after a successful pre-Investigational New Drug Application (IND) meeting, the US Food and Drug Administration (FDA) has given positive feedback on its […] July 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 AstraZeneca adds to its treatments for blood cancer with $100M deal AstraZeneca announced today (July 5) it has agreed to buy a company working on a cancer cure. The company will hand over $100 million for TeneoTwo, Inc. in an upfront payment that will include its phase 1 clinical-stage CD19/CD3 T-cell engager, TNB-486, that is being evaluated in relapsed and refractory B-cell non-Hodgkin lymphoma. With the […] July 5, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 5 Jul 2022 The biggest US biotech investments in June 2022 In addition to recent Independence Day festivities, the U.S. biotech space has other reasons to celebrate. The asthma drug developer Upstream Bio topped the ranks for the U.S.’ biggest early-stage biotech investment in June 2022, but manufacturing heavyweight National Resilience, Inc. bagged the private funding top spot with a huge Series D round. In June […] July 5, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Brii Bio takes hepatitis B treatment option Brii Biosciences Limited, based in China and the U.S., has exercised its option to acquire exclusive development and commercialization rights for VIR-3434 in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. VIR-3434, also known as BRII-877, is a broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) that is currently in […] July 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2022 Nanoparticle can kill cancer cells and aid muscle relaxation A nanoparticle that is both a nanoheater and a nanothermometer at the same time has been developed by researchers at a Japanese university. The university said this is a significant development that not only aids muscle relaxation, but it can also kill cancer cells. Satoshi Arai and colleagues at Kanazawa University have successfully showed that […] July 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2022 New home for wet lab incubator in bid to help biotech start-ups and promote life sciences A lab to bring together the hive minds of those addressing the future challenges in healthcare, including biotech start-ups, is set to open at Discovery Park, Kent, U.K. Barclays has selected the location as the home for its latest Eagle Lab, which will open later this year. The labs are a growing national network currently at […] July 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 4 Jul 2022 The COVID-19 pandemic has driven RNA therapeutics into the mainstream As messenger RNA vaccines save lives around the world, and RNA interference drugs are greenlit for rare diseases, the field of RNA therapeutics is now moving faster than ever before. The COVID-19 pandemic proved a turning point for the biotech companies BioNTech and Moderna, which specialize in developing technology based on messenger RNA (mRNA). The […] July 4, 2022 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2022 U.S. biotech financing drops 46% in Q1 compared to 2021 Venture financing deal value for U.S.-headquartered biotech companies dipped by 46% in Q1 2022 compared to Q1 2021, according to analysis from GlobalData. The data and analytics company said the decrease was due to venture capital firms becoming more selective in their investments due to the current economic and geopolitical uncertainties. Mariam Shwea, business fundamentals […] July 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 Progress for hearing preservation trial after Australian approval granted Approval has been granted by the Australian authorities to allow a French company to progress with a clinical trial testing cochlear implants. Montpellier-based Sensorion will start its proof of concept trial of SENS-401, a drug candidate that aims to protect and preserve inner ear tissue from damage. Sensorion is a biotech company specializing in the […] July 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 Companies come together in fight against Dengue Fever A vaccine to treat dengue fever, the mosquito-borne disease, is the end goal of two companies who have signed an agreement to produce and commercialize a lead candidate in the fight against the disease. Emergex Vaccines Holding Limited, a clinical-stage biotech company, recently announced that it has agreed a collaboration with the Molecular Biology Institute […] July 1, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 License submitted to FDA for drug to help those with large B-cell lymphoma A biologics license application has been submitted to the US Food and Drug Administration (FDA) for an antibody to treat patients with B-cell lymphoma. Genmab A/S is a biotechnology company that says its core purpose is to improve the lives of people with cancer. Recently it announced its intent to submit the application for subcutaneous […] July 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email